Overview
Halozyme Therapeutics, Inc., based in the United States, operates primarily within the biotechnology sector focusing on the development and commercialization of novel oncology therapies and drug delivery platforms. Key to its innovation, Halozyme has developed the proprietary ENHANZE® technology, a drug delivery platform that improves the absorption and dispersion of injected drugs. The company leverages this technology to formulate partnerships with other pharmaceutical entities, enhancing the bioavailability of blockbuster biologics. In its project portfolio, Halozyme focuses on utilizing its technology to facilitate subcutaneous delivery of intravenously administered therapies, aiming to improve patient experience and adherence. Furthermore, the company actively explores new therapeutic areas, including developing its own oncology pipeline centered on targeted treatments for various cancers.
Basic Stats
The Factor Analysis chart (below right) shows a view of Halozyme Therapeutics, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 134.97 MM |
| Earnings Date | |
| EPS (TTM) | 0.96 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | 0.00 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | 1.41 |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 5.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Halozyme Therapeutics, Inc. is MX$50.49. The forecasts range from a low of MX$21.21 to a high of MX$66.15. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
| Record Date | Projection Date | High | Low | Median | Average |
|---|---|---|---|---|---|
| 2023-04-02 | 2024-04-02 | 66.15 | 21.21 | 54.57 | 50.49 |
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Halozyme Therapeutics, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2024-09-13 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-25 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-07-22 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2025-08-18 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2024-10-25 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-07-16 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-06-26 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-06-25 | Benchmark | Buy | Buy | Maintains |
| 2024-06-24 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-06-07 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-06-07 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-06-07 | Piper Sandler | Overweight | Neutral | Downgrade |
| 2024-06-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-22 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-08 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-05-08 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-07 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-04-30 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-04-17 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-04-16 | Benchmark | Buy | Buy | Reiterate |
| 2024-02-29 | TD Cowen | Outperform | Initiate | |
| 2024-02-21 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-02-21 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-01-19 | Benchmark | Buy | Buy | Reiterate |
| 2024-01-19 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-01-18 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-01-18 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2024-01-18 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-12-26 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-10-20 | Benchmark | Buy | Buy | Reiterate |
| 2023-10-19 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-10-09 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-09-08 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-08-30 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-08-15 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-08-10 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-07-24 | HC Wainwright & Co. | Buy | Initiate | |
| 2023-07-24 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2023-05-10 | JMP Securities | Market Outperform | Reiterate | |
| 2023-05-10 | Morgan Stanley | Overweight | Maintains | |
| 2023-05-10 | Piper Sandler | Neutral | Overweight | Upgrade |
| 2023-03-27 | Berenberg | Buy | Reiterate | |
| 2023-03-17 | Wells Fargo | Overweight | Maintains | |
| 2023-03-16 | Wells Fargo | Overweight | Maintains | |
| 2023-03-16 | SVB Leerink | Outperform | Market Perform | Downgrade |
| 2023-03-06 | Morgan Stanley | Overweight | Maintains | |
| 2023-02-23 | JP Morgan | Overweight | Maintains | |
| 2023-02-22 | JMP Securities | Market Outperform | Reiterate | |
| 2023-01-11 | SVB Leerink | Outperform | Maintains | |
| 2022-12-21 | Morgan Stanley | Overweight | Maintains | |
| 2022-12-08 | Benchmark | Buy | Maintains | |
| 2022-11-28 | Wells Fargo | Overweight | Initiate | |
| 2022-11-22 | JP Morgan | Overweight | Maintains | |
| 2022-11-14 | SVB Leerink | Outperform | Maintains | |
| 2022-11-09 | JMP Securities | Market Outperform | Maintains | |
| 2022-09-09 | Morgan Stanley | Overweight | Initiate | |
| 2022-05-26 | Goldman Sachs | Buy | Maintains | |
| 2022-05-11 | JMP Securities | Market Outperform | Maintains | |
| 2021-11-24 | Wells Fargo | Overweight | Maintains | |
| 2021-11-03 | JMP Securities | Market Outperform | Maintains | |
| 2021-11-03 | SVB Leerink | Outperform | Maintains | |
| 2021-06-14 | Evercore ISI Group | Outperform | Initiate | |
| 2021-05-17 | SVB Leerink | Outperform | Initiate | |
| 2021-05-11 | Piper Sandler | Overweight | Neutral | Downgrade |
| 2020-12-17 | Berenberg | Buy | Initiate | |
| 2020-11-16 | Wells Fargo | Overweight | Maintains | |
| 2020-07-02 | Piper Sandler | Overweight | Maintains | |
| 2020-07-01 | Benchmark | Buy | Initiate | |
| 2020-06-15 | Citigroup | Neutral | Maintains | |
| 2020-05-19 | Canaccord Genuity | Buy | Maintains | |
| 2020-05-12 | BMO Capital | Outperform | Maintains | |
| 2020-05-12 | JP Morgan | Overweight | Maintains | |
| 2020-05-12 | JMP Securities | Market Outperform | Maintains | |
| 2020-05-04 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2020-02-25 | Barclays | Equal-Weight | Maintains | |
| 2020-02-25 | JP Morgan | Overweight | Maintains | |
| 2020-02-05 | Piper Sandler | Neutral | Overweight | Upgrade |
| 2020-01-27 | Cantor Fitzgerald | Overweight | Maintains | |
| 2020-01-09 | BMO Capital | Market Perform | Outperform | Upgrade |
| 2020-01-08 | Goldman Sachs | Buy | Initiate | |
| 2019-11-20 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2019-11-13 | BMO Capital | Market Perform | Maintains | |
| 2019-11-13 | JP Morgan | Overweight | Maintains | |
| 2019-11-05 | Barclays | Underweight | Equal-Weight | Upgrade |
| 2018-08-23 | Cantor Fitzgerald | Overweight | Initiate | |
| 2018-08-08 | BMO Capital | Market Perform | Market Perform | Maintains |
| 2018-05-11 | Barclays | Equal-Weight | Underweight | Downgrade |
| 2018-02-22 | BMO Capital | Market Perform | Market Perform | Maintains |
| 2018-02-21 | JP Morgan | Overweight | Overweight | Maintains |
| 2018-01-24 | Goldman Sachs | Neutral | Initiate | |
| 2017-11-08 | Canaccord Genuity | Buy | Maintains | |
| 2017-11-08 | BMO Capital | Market Perform | Maintains | |
| 2017-09-15 | BMO Capital | Market Perform | Maintains | |
| 2017-04-17 | BMO Capital | Market Perform | Initiate | |
| 2016-11-03 | Deutsche Bank | Buy | Initiate | |
| 2016-09-16 | PiperJaffray | Overweight | Maintains | |
| 2016-03-09 | JMP Securities | Market Outperform | Maintains | |
| 2016-02-24 | Barclays | Overweight | Maintains | |
| 2016-02-01 | Canaccord Genuity | Buy | Initiate | |
| 2015-11-18 | Citigroup | Buy | Initiate | |
| 2015-09-22 | Barclays | Overweight | Initiate | |
| 2015-08-11 | JMP Securities | Market Outperform | Maintains | |
| 2015-06-04 | JMP Securities | Market Outperform | Maintains | |
| 2015-03-03 | BMO Capital | Outperform | Maintains | |
| 2015-01-08 | JP Morgan | Overweight | Maintains | |
| 2014-12-24 | MLV & Co. | Buy | Initiate | |
| 2014-12-09 | JP Morgan | Overweight | Maintains | |
| 2014-09-15 | Jefferies | Underperform | Maintains | |
| 2014-07-11 | JP Morgan | Outperform | Initiate | |
| 2014-06-11 | UBS | Neutral | Buy | Upgrade |
| 2014-04-15 | Citigroup | Buy | Initiate | |
| 2013-08-02 | Barclays | Overweight | Equal-Weight | Downgrade |
| 2013-05-14 | PiperJaffray | Overweight | Initiate | |
| 2013-05-01 | UBS | Neutral | Maintains | |
| 2013-02-01 | BMO Capital | Outperform | Maintains | |
| 2013-01-30 | Wedbush | Outperform | Neutral | Downgrade |
| 2013-01-14 | BMO Capital | Market Perform | Outperform | Upgrade |
| 2012-11-09 | Barclays | Overweight | Maintains | |
| 2012-10-08 | Wedbush | Outperform | Maintains | |
| 2012-09-27 | UBS | Neutral | Initiate | |
| 2012-09-24 | Barclays | Overweight | Maintains | |
| 2012-09-24 | Jefferies | Underperform | Maintains | |
| 2012-09-21 | Jefferies | Underperform | Maintains | |
| 2012-08-02 | Barclays | Overweight | Maintains | |
| 2012-08-02 | Jefferies | Hold | Underperform | Downgrade |
| 2012-04-17 | Jefferies | Hold | Maintains | |
| 2012-04-17 | Wedbush | Outperform | Maintains | |
| 2012-04-16 | Brean Capital | Buy | Maintains | |
| 2012-04-16 | Oppenheimer | Outperform | Maintains | |
| 2025-02-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-06 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-11-04 | Piper Sandler | Neutral | Neutral | Maintains |
| 2024-11-01 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-11-01 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-11-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-01 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-08 | Benchmark | Buy | Buy | Reiterate |
| 2024-08-08 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-07 | TD Cowen | Buy | Buy | Maintains |
| 2024-08-07 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2024-10-07 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| 2024-10-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-03-06 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-12-18 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-10 | Piper Sandler | Neutral | Neutral | Maintains |
| 2025-01-10 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-12-30 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-13 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2024-09-19 | JP Morgan | Overweight | Neutral | Downgrade |
| 2024-09-16 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-20 | Benchmark | Buy | Buy | Reiterate |
| 2025-02-19 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-04-25 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-05-13 | Leerink Partners | Market Perform | Underperform | Downgrade |
| 2025-05-14 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2025-05-07 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2025-07-16 | JP Morgan | Neutral | Neutral | Maintains |
| 2025-04-21 | JP Morgan | Neutral | Neutral | Maintains |
| 2025-08-07 | JP Morgan | Neutral | Neutral | Maintains |
| 2025-08-06 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2025-08-06 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-08-06 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2025-05-29 | HC Wainwright & Co. | Buy | Buy | Reiterate |
